Physiomics Regulatory News (PYC)

4 March 2021

Physiomics plc

("Physiomics") or (the "Company")

Interim Results Presentation

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that the Company's CEO, Jim Millen, will provide a live presentation relating to its interim results for the six-month period ended 31 December 2020, via the Investor Meet Company platform, on 11 Mar 2021, at 11:00am GMT.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event, via the Investor Meet Company dashboard, up until 9:00am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and register their interest in Physiomics plc, using the following link:

https://www.investormeetcompany.com/physiomics-plc/register-investor

Investors who already follow Physiomics plc on the Investor Meet Company platform will automatically be invited.

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0) 20 7409 3494

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 80 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.